These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. Awasthi S; Lubinski JM; Shaw CE; Barrett SM; Cai M; Wang F; Betts M; Kingsley S; Distefano DJ; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM J Virol; 2011 Oct; 85(20):10472-86. PubMed ID: 21813597 [TBL] [Abstract][Full Text] [Related]
12. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge. Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297 [TBL] [Abstract][Full Text] [Related]
13. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Odegard JM; Flynn PA; Campbell DJ; Robbins SH; Dong L; Wang K; Ter Meulen J; Cohen JI; Koelle DM Vaccine; 2016 Jan; 34(1):101-9. PubMed ID: 26571309 [TBL] [Abstract][Full Text] [Related]
14. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes. Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells. Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105 [TBL] [Abstract][Full Text] [Related]
16. Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+CD44+ CD62L-CD8+ T Cells and Memory CCR10+B220+CD27+ B Cells into the Infected Vaginal Mucosa. Dhanushkodi NR; Prakash S; Quadiri A; Zayou L; Srivastava R; Tran J; Dang V; Shaik AM; Chilukurri A; Suzer B; Vera P; Sun M; Nguyen P; Lee A; Salem A; Loi J; Singer M; Nakayama T; Vahed H; Nesburn AB; BenMohamed L J Immunol; 2023 Jul; 211(1):118-129. PubMed ID: 37222480 [TBL] [Abstract][Full Text] [Related]
17. Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease. Bourne N; Keith CA; Miller AL; Pyles RB; Cohen G; Milligan GN J Virol; 2023 Sep; 97(9):e0066923. PubMed ID: 37655939 [TBL] [Abstract][Full Text] [Related]
18. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Morello CS; Kraynyak KA; Levinson MS; Chen Z; Lee KF; Spector DH Vaccine; 2012 Oct; 30(46):6541-6550. PubMed ID: 22947141 [TBL] [Abstract][Full Text] [Related]
19. Bolstering the Number and Function of HSV-1-Specific CD8 Khan AA; Srivastava R; Chentoufi AA; Kritzer E; Chilukuri S; Garg S; Yu DC; Vahed H; Huang L; Syed SA; Furness JN; Tran TT; Anthony NB; McLaren CE; Sidney J; Sette A; Noelle RJ; BenMohamed L J Immunol; 2017 Jul; 199(1):186-203. PubMed ID: 28539429 [TBL] [Abstract][Full Text] [Related]
20. Increased Frequency of Virus Shedding by Herpes Simplex Virus 2-Infected Guinea Pigs in the Absence of CD4 Bourne N; Perry CL; Banasik BN; Miller AL; White M; Pyles RB; Schäfer H; Milligan GN J Virol; 2019 Feb; 93(4):. PubMed ID: 30463981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]